A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer

Trial Profile

A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Ranpirnase (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Tamir Biotechnology
  • Most Recent Events

    • 25 Aug 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 18 Jan 2011 Planned end date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 23 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top